GlassScriptPhysician profile
Nannaya Jampala
NPI 1649690637
$88,041.59
in general payments reported to CMS, 2019-2025
27 companies · $19K in 2025
The $19K reported for 2025 was more than what 95% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $41.71 · 2022: $10K · 2023: $21K · 2024: $37K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $58K · Travel and Lodging: $8,900 · Food and Beverage: $7,832 · Consulting Fee: $3,000 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $57,896.36 |
| Travel and Lodging | $8,900.46 |
| Food and Beverage | $7,831.71 |
| Consulting Fee | $3,000.00 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $60,732.10 | 2022-2025 | |
| Pfizer INC. | $15,953.34 | 2020-2025 | |
| Janssen Biotech, INC. | $8,005.13 | 2023-2025 | Tremfya, Stelara |
| Phathom Pharmaceuticals, INC. | $378.10 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $359.88 | 2022-2025 | Entyvio, Gattex, Eohilia |
| Lilly USA, LLC | $329.50 | 2024-2025 | Omvoh, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $323.93 | 2020-2025 | Xifaxan, Trulance, Plenvu |
| Boston Scientific Corporation | $310.70 | 2022-2025 | Exalt Model D, General - Hemostasis |
| Qol Medical, LLC | $259.37 | 2022-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $192.59 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $170.80 | 2022-2024 | Dupixent |
| Intercept Pharmaceuticals, INC. | $165.58 | 2022-2025 | Ocaliva |
| Ardelyx, INC. | $161.10 | 2023-2025 | Ibsrela |
| Celltrion USA INC. | $131.54 | 2024-2025 | Vegzelma |
| Celgene Corporation | $125.48 | 2022-2024 | Zeposia |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $102.78 | 2024-2025 | Iqirvo, Bylvay |
| Merck Sharp & Dohme LLC | $77.75 | 2022-2024 | Dificid |
| Intra-Sana Laboratories | $47.38 | 2022 | |
| Exact Sciences Corporation | $38.52 | 2023 | Cologuard Collection Kit |
| Braintree Laboratories, INC. | $35.98 | 2024 | Sutab, Suflave |
| Amgen INC. | $27.29 | 2023 | Avsola, Amjevita |
| Organon LLC | $23.95 | 2023 | Hadlima |
| Aimmune Therapeutics, INC. | $20.15 | 2025 | Zenpep |
| Madrigal Pharmaceuticals | $18.79 | 2025 | Rezdiffra |
| Fresenius Kabi USA, LLC | $18.06 | 2024 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.08 | 2023 | Cyltezo |
| Biocon Biologics INC | $14.72 | 2025 | Yesintek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nannaya Jampala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.